"The market seems to be fairly positive and there is momentum building in the UK for pharmaceuticals investments. At the same time, we are absolutely not an R&D company; we are a development and commercialization company. If you look at our funding history, we have always delivered against our plan. We will have our first revenues next year."
Carl Sterritt, CEO, Shield Therapeutics Ltd., which is raising up to $168 million in an IPO on the London Stock Exchange

"The object of our international regulatory harmonization strategy is to proactively contribute to the international regulatory harmonization and cooperation by disseminating Japan's knowledge on regulations to the world. We aim to resolve the global drug and medical device lag and contribute to global health as well as revitalize the pharmaceutical and medical device industries."
Yuji Kanda, director general of the Pharmaceutical and Food Safety Bureau at the Ministry of Health, Labor and Welfare commenting on Japan's outreach to drug developers from around the world to attract more innovative products and emerge as a regional leader in the field

"Mitochondrial therapeutics is a great area for development, and that's Gencia's expertise. We're tremendously excited about this partnership with Takeda. We're excited to work with their team and we're excited to advance our platform and our major compounds into the clinic."
Allen Cunningham, co-founder, president and CEO of Gencia LLC, discussing its potential $500M discovery deal with Takeda Pharmaceutical Co. Ltd.